4. Perl AE, Altman JK, Cortes J, et al: Selective inhibition of FLT3 by gilteritinib in relapsed or
refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet
Oncol 18:1061-1075, 2017
5. Cortes JE KH, Kadia TM, Borthakur G, Konopleva M, Garcia-Manero G, Daver NG,
Pemmaraju N, Jabbour E, Estrov Z, Ramachandran A, Paradela J, Pond B, Ravandi F, Vusirikala M, Patel
PA, Levis MJ, Perl AE, Andreeff M, Collins R: Crenolanib Besylate, a Type I Pan-FLT3 Inhibitor,
Demonstrates Clinical Activity in Multiply Relapsed FLT3-ITD and D835 AML. J Clin Oncol 34:suppl; abstr
7008, 2016
6. Cortes JE, Khaled S, Martinelli G, et al: Quizartinib versus salvage chemotherapy in
relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised,
controlled, open-label, phase 3 trial. Lancet Oncol 20:984-997, 2019
7. Perl AE, Martinelli G, Cortes JE, et al: Gilteritinib or Chemotherapy for Relapsed or
Refractory FLT3-Mutated AML. N Engl J Med 381:1728-40, 2019
8. Pratz KW, Cherry M, Altman JK, et al: Updated Results from a Phase 1 Study of
Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly
Diagnosed Acute Myeloid Leukemia (AML). Blood 132:564-564, 2018
9. Altman JK, Foran JM, Pratz KW, et al: Results Of a Phase 1 Study Of Quizartinib (AC220,
ASP2689) In Combination With Induction and Consolidation Chemotherapy In Younger Patients With
Newly Diagnosed Acute Myeloid Leukemia. Blood 122:623a, 2013
10. Wang ES, Tallman MS, Stone RM, et al: Low Relapse Rate in Younger Patients ≤ 60 Years
Old with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) Treated with Crenolanib and
Cytarabine/Anthracycline Chemotherapy. Blood 130:566-566, 2017
11. Esteve J, Schots R, Bernal Del Castillo T, et al: Multicenter, Open-Label, 3-Arm Study of
Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated
(FLT3mut+) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy:
Findings from the Safety Cohort. Blood 132:2736-2736, 2018
12. Swaminathan M, Kantarjian HM, Daver N, et al: The Combination of Quizartinib with
Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid
Leukemias: Interim Report of a Phase I/II Trial. Blood 130:723-723, 2017
13. Perl AE, Daver NG, Pratz KW, et al: Venetoclax in Combination with Gilteritinib in
Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study. Blood 134:3910-3910,
2019
14. McMahon CM, Canaani J, Rea B, et al: Gilteritinib induces differentiation in relapsed and
refractory FLT3-mutated acute myeloid leukemia. Blood Adv 3:1581-1585, 2019
15. McMahon CM, Ferng T, Canaani J, et al: Clonal Selection with RAS Pathway Activation
Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. Cancer
Discov 9:1050-1063, 2019
16. Sexauer A, Perl A, Yang X, et al: Terminal myeloid differentiation in vivo is induced by
FLT3 inhibition in FLT3/ITD AML. Blood 120:4205-14, 2012
17. Perl AE: Availability of FLT3 inhibitors: how do we use them? Blood 134:741-745, 2019